Olema Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Olema Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($162.45M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($129.47M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($96.66M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($104.79M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($71.10M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($22.12M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | ($4.32M) | Feb 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($178.70M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($142.26M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($104.96M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($106.99M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($71.49M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($21.53M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | ($4.32M) | Feb 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $157.70M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $124.52M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $86.14M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $82.27M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $51.10M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $13.70M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $3.92M | Feb 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($146.72M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($104.35M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($83.73M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($82.07M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($50.69M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($19.87M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | ($3.08M) | Feb 28, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $159.0K | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $363.0K | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $1.58M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $56.0K | Feb 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $533.43M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $450.98M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $276.95M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $215.65M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $295.95M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $342.72M | Feb 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.87M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $42.02M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $23.05M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $18.10M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $11.38M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.59M | Feb 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $478.56M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $408.96M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $253.90M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $197.55M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $284.57M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $338.14M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | ($10.59M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2018 | ($8.40M) | Feb 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($597.56M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($435.11M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($305.63M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($208.98M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($104.19M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($33.09M) | Feb 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.30M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $139.48M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $68.54M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $23.70M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $13.81M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $338.55M | Feb 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 81.38M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 74.31M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 54.99M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 40.29M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 39.80M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 39.31M | Feb 28, 2022 |